Six people were wounded in Russian air strikes on Ukraine overnight on Tuesday, local authorities said, while Russia’s ongoing fuel crisis deepened into parts of Siberia.
Category: News
Lebanon heads into a new round of talks with Israel on Tuesday in Washington, with Beirut determined to press ahead with direct negotiations even as they appear to be overshadowed by Iran’s decision to make Lebanon part of its negotiations with the United States.
U.S. Secretary of State Marco Rubio faces a delicate mission this week pitching Washington’s Iran peace deal to Gulf Arab leaders who fear excessive concessions will strengthen Tehran and reshape the region’s security balance and oil flows.
The legal, political and commercial challenges of unwinding restrictions could take years.
The United States waived sanctions on Iran for 60 days from Monday after the first talks under a nascent peace deal, with U.S. President Donald Trump saying he will “do what I have to do” if Iran does not stick to its side of the agreement.
Just a short stroll from Sydney’s famous Bondi Beach, auctioneer Clarence White struggles to drum up bids for an airy three-storey home that boasts five bedrooms and an al fresco lounge – price tag, A$5.2 million ($3.64 million).
The global AI boom has turned South Korean chipmaking giants SK Hynix and Samsung Electronics into stock market darlings. It has also thrust their employees into the top tier of the country’s highly competitive marriage market.
Oil prices inched down on Tuesday, extending losses from the previous session, as investors looked for clearer signs of progress in restoring crude flows through the Strait of Hormuz following U.S.-Iran peace talks.
Patient access to new medicines is worsening across Europe, the region’s main pharmaceuticals industry lobby group said as it published research arguing that investment in innovative medicines generates substantial economic and social returns.
Definium Therapeutics said a single dose of its LSD-based experimental pill significantly reduced symptoms of major depression in patients in a late-stage trial, sending its shares soaring 55% to a more than four-year high on Monday.